Sharon R. Lewin Department of Infectious Diseases The University of Melbourne at the Peter Doherty Institute for Infection and Immunity Biography Publications Institution JoVE Articles Sharon R. Lewin has not added a biography. If you are Sharon R. Lewin and would like to personalize this page please email our Author Liaison for assistance. Publications Nafamostat Mesylate for Treatment of COVID-19 in Hospitalised Patients: A Structured, Narrative Review Clinical Pharmacokinetics. Aug, 2022 | Pubmed ID: 36040613 The Role of Latency Reversal in HIV Cure Strategies Journal of Medical Primatology. Oct, 2022 | Pubmed ID: 36029233 Intact HIV Proviruses Persist in the Brain Despite Viral Suppression with ART Annals of Neurology. Oct, 2022 | Pubmed ID: 35867351 Factors Associated with Weak Positive SARS-CoV-2 Diagnosis by Reverse Transcriptase-quantitative Polymerase Chain Reaction (RT-qPCR) Pathology. Aug, 2022 | Pubmed ID: 35778288 Detection of Chimeric Cellular: HIV MRNAs Generated Through Aberrant Splicing in HIV-1 Latently Infected Resting CD4+ T Cells Frontiers in Cellular and Infection Microbiology. 2022 | Pubmed ID: 35573784 Antiretroviral Initiation at ≥800 CD4+ Cells/ Mm 3 Associated with Lower HIV Reservoir Size Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America. Apr, 2022 | Pubmed ID: 35396591 Nanoscale Probing and Imaging of HIV-1 RNA in Cells with a Chimeric LNA-DNA Sensor Nanoscale. Feb, 2022 | Pubmed ID: 35142755 Immune Checkpoint Blockade in HIV EBioMedicine. Feb, 2022 | Pubmed ID: 35123267 Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy Journal of Immunology (Baltimore, Md. : 1950). 01, 2022 | Pubmed ID: 34853078 Cell-Associated Human Immunodeficiency Virus (HIV) Ribonucleic Acid Has a Circadian Cycle in Males With HIV on Antiretroviral Therapy The Journal of Infectious Diseases. 05, 2022 | Pubmed ID: 34655216 Research Priorities for an HIV Cure: International AIDS Society Global Scientific Strategy 2021 Nature Medicine. 12, 2021 | Pubmed ID: 34848888 Consensus Statement on the Role of Health Systems in Advancing the Long-term Well-being of People Living with HIV Nature Communications. 07, 2021 | Pubmed ID: 34272399 Reprogrammed CRISPR-Cas13b Suppresses SARS-CoV-2 Replication and Circumvents Its Mutational Escape Through Mismatch Tolerance Nature Communications. 07, 2021 | Pubmed ID: 34257311 The RNA-Binding Proteins SRP14 and HMGB3 Control HIV-1 Tat MRNA Processing and Translation During HIV-1 Latency Frontiers in Genetics. 2021 | Pubmed ID: 34194479 Multi-site Assessment of Rapid, Point-of-care Antigen Testing for the Diagnosis of SARS-CoV-2 Infection in a Low-prevalence Setting: A Validation and Implementation Study The Lancet Regional Health. Western Pacific. Apr, 2021 | Pubmed ID: 33937887 The Impact of Immune Checkpoint Therapy on the Latent Reservoir in HIV-infected Individuals with Cancer on Antiretroviral Therapy AIDS (London, England). 08, 2021 | Pubmed ID: 33859108 Multiply Spliced HIV RNA is a Predictive Measure of Virus Production Ex Vivo and in Vivo Following Reversal of HIV Latency EBioMedicine. Mar, 2021 | Pubmed ID: 33647768 Multi-stakeholder Consensus on a Target Product Profile for an HIV Cure The Lancet. HIV. 01, 2021 | Pubmed ID: 33271125 Leveraging the Advances in HIV for COVID-19 Lancet (London, England). 10, 2020 | Pubmed ID: 33010825 Evaluation of Serological Tests for SARS-CoV-2: Implications for Serology Testing in a Low-Prevalence Setting The Journal of Infectious Diseases. 09, 2020 | Pubmed ID: 32761124 Breadth of Concomitant Immune Responses Prior to Patient Recovery: a Case Report of Non-severe COVID-19 Nature Medicine. 04, 2020 | Pubmed ID: 32284614 A Cure for HIV: How Would We Know? The Lancet. HIV. 05, 2020 | Pubmed ID: 32169159 Kick and Kill for HIV Latency Lancet (London, England). 03, 2020 | Pubmed ID: 32085822 Combination Immune Checkpoint Blockade to Reverse HIV Latency Journal of Immunology (Baltimore, Md. : 1950). 03, 2020 | Pubmed ID: 31988180 CXCR4-Using HIV Strains Predominate in Naive and Central Memory CD4 T Cells in People Living with HIV on Antiretroviral Therapy: Implications for How Latency Is Established and Maintained Journal of Virology. 02, 2020 | Pubmed ID: 31852784 Limitations of Dual-fluorescent HIV Reporter Viruses in a Model of Pre-activation Latency Journal of the International AIDS Society. 12, 2019 | Pubmed ID: 31855322 Tesamorelin, Liver Fat, and NAFLD in the Setting of HIV The Lancet. HIV. 12, 2019 | Pubmed ID: 31611037 CD4 T Cell Signatures in HIV Infection Nature Immunology. 08, 2019 | Pubmed ID: 31308542 Between a Shock and a Hard Place: Challenges and Developments in HIV Latency Reversal Current Opinion in Virology. 10, 2019 | Pubmed ID: 31048093 Functional Cure of HIV: the Scale of the Challenge Nature Reviews. Immunology. 01, 2019 | Pubmed ID: 30410126 Strategies for an HIV Cure: Progress and Challenges Nature Immunology. 11, 2018 | Pubmed ID: 30333614 Barriers and Strategies to Achieve a Cure for HIV The Lancet. HIV. 06, 2018 | Pubmed ID: 29893245 The Pathway To Establishing HIV Latency Is Critical to How Latency Is Maintained and Reversed Journal of Virology. 07, 2018 | Pubmed ID: 29643247 The Effect of Antiretroviral Intensification with Dolutegravir on Residual Virus Replication in HIV-infected Individuals: a Randomised, Placebo-controlled, Double-blind Trial The Lancet. HIV. 05, 2018 | Pubmed ID: 29643011 Getting the "Kill" into "Shock and Kill": Strategies to Eliminate Latent HIV Cell Host & Microbe. Jan, 2018 | Pubmed ID: 29324227 Modeling of Antilatency Treatment in HIV: What Is the Optimal Duration of Antiretroviral Therapy-Free HIV Remission? Journal of Virology. 12, 2017 | Pubmed ID: 29021399 Editorial: HIV and Lipopolysaccharide: Double Trouble in the Liver Journal of Leukocyte Biology. 05, 2017 | Pubmed ID: 28468986 No Adverse Safety or Virological Changes 2 Years Following Vorinostat in HIV-infected Individuals on Antiretroviral Therapy AIDS (London, England). 05, 2017 | Pubmed ID: 28301423 HealthMap: a Cluster Randomised Trial of Interactive Health Plans and Self-management Support to Prevent Coronary Heart Disease in People with HIV BMC Infectious Diseases. Mar, 2016 | Pubmed ID: 26945746 HIV Reactivation from Latency After Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission PLoS Pathogens. Jul, 2015 | Pubmed ID: 26133551 İlaç Dağıtım Sistemleri ve Hücreler Arasındaki Etkileşimlerin Deneysel Ölçümü In Vitro: Preklinik Nanotıp Değerlendirmesi İçin Bir Kılavuz Paula M. Cevaal1, Michael Roche2, Sharon R. Lewin2,3,4, Frank Caruso5, Matthew Faria6 1Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, 2Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, 3Victorian Infectious Diseases Service, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, 4Department of Infectious Diseases, Alfred Hospital and Monash University, 5Department of Chemical Engineering, The University of Melbourne, 6Department of Biomedical Engineering, The University of Melbourne JoVE 64259 Bioengineering
İlaç Dağıtım Sistemleri ve Hücreler Arasındaki Etkileşimlerin Deneysel Ölçümü In Vitro: Preklinik Nanotıp Değerlendirmesi İçin Bir Kılavuz Paula M. Cevaal1, Michael Roche2, Sharon R. Lewin2,3,4, Frank Caruso5, Matthew Faria6 1Department of Microbiology and Immunology, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, 2Department of Infectious Diseases, The University of Melbourne at the Peter Doherty Institute for Infection and Immunity, 3Victorian Infectious Diseases Service, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, 4Department of Infectious Diseases, Alfred Hospital and Monash University, 5Department of Chemical Engineering, The University of Melbourne, 6Department of Biomedical Engineering, The University of Melbourne JoVE 64259 Bioengineering
